Search

This document provides the final report of a scoping review undertaken as part of a wider study on the ‘Assessment of point of care testing devices for infectious disease surveillance, prevention and control’ that was commissioned by ECDC and undertaken by RAND Europe between November 2019 and April 2020. 

This document provides the final report of a mapping exercise undertaken as part of a wider study that was commissioned by ECDC and undertaken by RAND Europe between November 2019 and April 2020. 

The aim of this report is to independently evaluate the Belgian SARS-CoV testing policy to support an optimal and sustainable testing policy for public health purposes.

This report is the first update of a brief technical note that was developed at the request of the European Commission to inform the discussion on Digital Green Certificates to facilitate the safe and free movement of citizens within the EU during the COVID-19 pandemic.

This document is the first update of the technical report ‘Options for the use of rapid antigen detection tests (RADTs) for COVID-19 in the EU/EEA’. It is intended to facilitate further discussions between Member States on the settings and purpose for which it is appropriate to use RADTs and summarises key considerations for their implementation. Reaching an agreement on settings and performance criteria will be critical for the success of EU/EEA-wide surveillance purposes and for measures related to cross-border travel.

This document outlines the public health considerations for the use of rapid antigen detection tests (RADTs), including self-test RADTs to detect SARS-CoV-2 in individuals in occupational settings in the European Union/European Economic Area (EU/EEA), and provides information on the use of such tests in an occupational safety and health at work context.

This document outlines the use of saliva as a diagnostic sample for detecting SARS-CoV-2 infection, considering the advantages, limitations and uncertainties associated with the use of saliva as sample material.

This brief will present a snapshot of hepatitis B and C testing in the European Union/European Economic Area (EU/EEA), discussing progress made towards the European action plan 2020 testing target, focussing on key populations and settings for testing, barriers to testing, and testing policies.